Free Trial
NASDAQ:PYPD

PolyPid (PYPD) Stock Price, News & Analysis

PolyPid logo
$3.20
-0.34 (-9.60%)
(As of 10/31/2024 ET)

About PolyPid Stock (NASDAQ:PYPD)

Key Stats

Today's Range
$3.20
$3.55
50-Day Range
$3.15
$3.68
52-Week Range
$2.95
$9.20
Volume
7,749 shs
Average Volume
6,179 shs
Market Capitalization
$15.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00
Consensus Rating
Buy

Company Overview

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

PolyPid Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
53rd Percentile Overall Score

PYPD MarketRank™: 

PolyPid scored higher than 53% of companies evaluated by MarketBeat, and ranked 543rd out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PolyPid has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    PolyPid has only been the subject of 1 research reports in the past 90 days.

  • Read more about PolyPid's stock forecast and price target.
  • Earnings Growth

    Earnings for PolyPid are expected to grow in the coming year, from ($4.39) to ($2.21) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PolyPid is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PolyPid is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about PolyPid's valuation and earnings.
  • Percentage of Shares Shorted

    0.21% of the float of PolyPid has been sold short.
  • Short Interest Ratio / Days to Cover

    PolyPid has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PolyPid has recently increased by 6.85%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    PolyPid does not currently pay a dividend.

  • Dividend Growth

    PolyPid does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.21% of the float of PolyPid has been sold short.
  • Short Interest Ratio / Days to Cover

    PolyPid has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PolyPid has recently increased by 6.85%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    PolyPid has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for PolyPid this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added PolyPid to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PolyPid insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 26.47% of the stock of PolyPid is held by institutions.

  • Read more about PolyPid's insider trading history.
Receive PYPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter.

PYPD Stock News Headlines

Rosalind Advisors, Inc. Reduces Stake in PolyPid Ltd
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
PolyPid completes enrollment for phase 3 trial
See More Headlines

PYPD Stock Analysis - Frequently Asked Questions

PolyPid's stock was trading at $3.80 at the beginning of 2024. Since then, PYPD shares have decreased by 15.8% and is now trading at $3.20.
View the best growth stocks for 2024 here
.

PolyPid Ltd. (NASDAQ:PYPD) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($1.51) by $0.26.

Shares of PolyPid reverse split on Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

PolyPid (PYPD) raised $50 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 3,100,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.

Top institutional investors of PolyPid include Rosalind Advisors Inc. (14.16%).

Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that PolyPid investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Teladoc Health (TDOC), CrowdStrike (CRWD), PayPal (PYPL) and Roku (ROKU).

Company Calendar

Last Earnings
8/14/2024
Today
10/31/2024
Next Earnings (Estimated)
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:PYPD
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$14.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+295.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-23,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.27) per share

Miscellaneous

Free Float
3,612,000
Market Cap
$16.98 million
Optionable
No Data
Beta
1.32
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:PYPD) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners